Skip to main content
OpenTrials
Completed

NCT Number: NCT03102450

Contraceptive Efficacy, Tolerance and Acceptability of a Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age

In spite of many advantages of spermicides, there is no contraceptive efficacy study conducted with any spermicide in women aged over 40 years. That is why the aim of this study is to evaluate contraceptive efficacy, tolerance and acceptability of a spermicide with benzalkonium chloride (Pharmatex® cream) in women aged over 40 years.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

40 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Cabinet Gynecologie, Carnoux-en-Provence, France

Loading trial locations.

About this study

Not all contraceptive methods are appropriate for all situations, and the most appropriate method of birth control depends on the woman's overall health, her age, the frequency of her sexual activity, her sexual partners, her desire to have children in the future, and personal or family history of certain diseases.

A special interest should be paid to women aged over 40 years. Decreased fertility, increased cardiovascular risks and greater exposure to gynecological disorders during perimenopause have led to reassess the contraceptive methods in this age group. Official guidelines allow the use of any contraceptive method - including combined estrogen progestin contraceptives (COCs) - that it had been well tolerated previously.

However, more frequent contraindications during perimenopause can lead women to switch to other methods, such as the intrauterine device, the progestin-only contraception or sterilization. In this context, local contraception with spermicides represents an attractive alternative for perimenopausal women. Being totally safe, particularly metabolically, the use of spermicides in this age group is not restricted by national and international guidelines except in HIV high risk women or women with HIV clinical disease.

Furthermore, the lubricating effect of a galenic formulation of spermicides, such as cream, is particularly useful in cases of vaginal dryness, which is common in perimenopausal women. Lastly, spermicides may be used in combination with other local methods of contraception. Considering the contraindications to other contraceptives, particularly hormonal contraceptives, and the greater risks associated with these methods during perimenopause, spermicides could be an appropriate alternative for a large number of perimenopausal women.

Today, in spite of many advantages of spermicides, there is no contraceptive efficacy study conducted with any spermicide in women aged over 40 years. That is why the aim of this study is to evaluate contraceptive efficacy, tolerance and acceptability of a spermicide with benzalkonium chloride (Pharmatex® cream) in women aged over 40 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women ≥ 40 years of age, fertile, having had at least one menstrual cycle in the course of the last three months
  • Women who were informed about the risks and benefits of all contraceptive methods, and for whom contraceptive methods other than spermicides were not suitable
  • Women who need a contraceptive method and who accept to use a spermicide for at least 6 months.
  • Women who have a negative pregnancy test at inclusion (the urinary pregnancy test should be performed at investigator's office then confirmed by a blood test performed in a local laboratory (quantitative beta hCG dosage)).))
  • Women who accept to comply with the requirements of the protocol including visits assessments and diary completion after each sexual intercourse
  • Women who have had a normal smear test < 3 years
  • Women affiliated to a public health insurance coverage
  • Women who have read, understood, dated and signed the informed consent form

Exclusion criteria

  • Women who are not able to understand a birth control method with Pharmatex® cream
  • Women who have had an unprotected sexual intercourse within 7 days before the Baseline Visit
  • Allergy or hypersensitivity to one of the components of Pharmatex® cream
  • Medical contraindication to pregnancy
  • Abnormal results of cervico-vaginal and/or vulvo-vaginal clinical examination (e.g. severe atrophic vaginitis etc.)
  • Women with history of > 2 induced abortions during lifetime (miscarriages and spontaneous abortions are not included)
  • Women with history of infectious vaginitis within the last 6 months
  • Women treated for STI within the last three months
  • HIV positive women and high-risk women for HIV
  • Breastfeeding women
  • Women participating or having participated in a clinical trial within four weeks prior to inclusion
  • Women deprived of liberty by a legal or administrative decision

Treatment and study plan

Benzalkonium Chloride Spermicide Cream

Drug

One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.

Duration of treatment : 6 months (12 months optional)

Other names: Pharmatex 1,2% vaginal cream

Primary outcomes

  1. Contraceptive Efficacy- PI over up to 12 months - typical use

    Time frame: up to 12 months after the inclusion

    Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) over up to 12 months of typical use. The Pearl Index is defined as the number of unintended pregnancies per 100 woman-years of a contraceptive method's use

    • Success: no fertilisation
    • Failure: unintended fertilisation (pregnancy or aborted pregnancy)

Secondary outcomes

  1. Contraceptive Efficacy - PI over up to 12 months - perfect use

    Time frame: up to 12 months after the inclusion

    Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) over up to 12 months of perfect use

  2. Contraceptive Efficacy - PI over up to 6 months - typical use

    Time frame: up to 6 months after the inclusion

    Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) at Visit 3 (M6) over up to 6 months of typical use

  3. Contraceptive Efficacy - PI over up to 6 months - perfect use

    Time frame: up to 6 months after the inclusion

    Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) at Visit 3 (M6) over up to 6 months of perfect use

  4. Contraceptive Efficacy - Pregnancy rate over up to 6 months - typical use

    Time frame: up to 6 months after the inclusion

    Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 6 months of typical use at Visit 3 (M6)

  5. Contraceptive Efficacy - Pregnancy rate over up to 6 months - perfect use

    Time frame: up to 6 months after the inclusion

    Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 6 months of perfect use at Visit 3 (M6)

  6. Contraceptive Efficacy - Pregnancy rate over up to 12 months - typical use

    Time frame: up to 12 months after the inclusion

    Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 12 months of typical use at Visit 4 (M12)

  7. Contraceptive Efficacy - Pregnancy rate over up to 12 months - perfect use

    Time frame: up to 12 months after the inclusion

    Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 12 months of perfect use at Visit 4 (M12)

  8. Number of adverse events

    Time frame: 6 or 12 months after the inclusion

    Number of adverse events during the study

  9. Percentage of adverse events

    Time frame: 6 or 12 months after the inclusion

    Percentage of adverse events during the study

  10. Acceptability - percentage of continuation

    Time frame: up to 6 or 12 months after the inclusion

    Evaluation of the acceptability of the treatment by percentage of continuation until the end of follow-up (at 6 months for all the women and at 12 months for women who have accepted to continue at visit 3 (M6))

  11. Acceptability - adherence

    Time frame: up to 6 or 12 months after the inclusion

    Evaluation of the acceptability of the treatment through adherence: systematic use of benzalkonium chloride spermicide before each event of sexual intercourse recorded in the self-evaluation diary

  12. Acceptability - ease of use (Likert scale)

    Time frame: up to 6 or 12 months after the inclusion

    Evaluation of the acceptability of the treatment (ease of use) evaluated through the self-evaluation diary (Likert scale) up to M6 (V3) and up to M12 (V4) for women who have continued for 12 months

  13. Acceptability - lubricating effect (Likert scale)

    Time frame: up to 6 or 12 months after the inclusion

    Evaluation of the acceptability of the treatment through the lubricating effect (Likert scale) at the end of study visit: V3 (M6), or V4 (M12) or at intermediate visit in case of early withdrawal

  14. Acceptability - global satisfaction of the woman (Likert scale)

    Time frame: 1, 2, 4, 6, 9, 12 months after the inclusion

    Evaluation of the global satisfaction of the treatment (Likert scale) by the woman at V2 (M2), V3 (M6) and V4 (M12) and during phone contacts PC1 (M1), PC2 (M4) and PC3 (M9)

  15. Acceptability - global satisfaction of the investigator (Likert scale)

    Time frame: 2, 6, 12 months after the inclusion

    Evaluation of the global satisfaction of the treatment (Likert scale) by the investigator at V2 (M2), V3 (M6) and V4 (M12).

Sponsors and collaborators

Lead sponsor

Laboratoire Innotech International

Industry

Collaborators

  • ITEC Services

Registry information

Acronym: BZK40+

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Apr 5, 2017
Registry last updated
Feb 26, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.